Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It mobilizes hematopoietic stem cells for autologous transplantation in patients with non‑Hodgkin lymphoma or multiple myeloma. Mozobil is authorized in the European Union and is supplied as a sterile, preservative‑free solution for clinical use.

GNH USA supplies Mozobil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Mozobil is employed to mobilize hematopoietic stem cells in hematologic malignancies.

- Non‑Hodgkin lymphoma: mobilizes stem cells to enable collection for autologous transplantation. - Multiple myeloma: mobilizes stem cells to enable collection for autologous transplantation. - Hematopoietic stem cell mobilization: enhances peripheral blood CD34+ cell yield to meet collection targets for autologous transplant procedures.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Injection site reactions: pain, erythema, or swelling at the subcutaneous site. - Diarrhea: loose stools occurring shortly after administration. - Fatigue: transient tiredness reported by many patients. - Headache: mild to moderate intensity. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Splenic rupture: rare but potentially life‑threatening abdominal event. - Severe allergic reaction: anaphylaxis with rash, bronchospasm, or hypotension. - Severe hypotension: marked drop in blood pressure requiring monitoring. - Leukocytosis: marked increase in white blood cell count. - Severe bone pain: intense musculoskeletal discomfort. - Tumor flare: rapid progression of underlying disease in rare cases.

Prior to administration, clinicians should consider several safety measures.

- Assess baseline CD34+ count: ensure adequate stem cell reserve before dosing. - Monitor for splenic enlargement: perform imaging if patients report abdominal pain. - Evaluate renal function: adjust use in patients with severe impairment. - Avoid concurrent use with other CXCR4 antagonists unless directed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mozobil may interact with other agents that affect stem cell dynamics or hemostasis.

Major Interactions (Avoid): - Co‑administration with other CXCR4 antagonists: may cause excessive stem cell mobilization. - Use with investigational agents that alter bone‑marrow niche: risk of unpredictable hematologic effects.

Moderate Interactions (Monitor Closely): - Concurrent granulocyte‑colony stimulating factor (G‑CSF): may increase leukocytosis. - Anticoagulants or antiplatelet drugs: heightened risk of injection‑site bleeding. - Diuretics: potential fluid‑balance changes influencing subcutaneous absorption.